QuickFISH® Rapid Differentiation of CoNS Directly from Blood Cultures
New study data on the OpGen QuickFISH® tests were presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held from April 9th to 12th in Amsterdam.
The studies were conducted at the NHS Royal Free Trust Hospital in London and were presented in two posters on Saturday, April 9th.
- Abstract #2455. Rapid differentiation of Staphylococcus aureus from coagulase-negative staphylococci directly from positive blood cultures: prospective comparison of four rapid methods; Rebecca Gorton, et al. - investigators concluded that QuickFISH rapidly differentiated Staphylococcus aureus from coagulase-negative staphylococci directly from blood cultures. It was the fastest and most cost-effective nucleic acid method evaluated with a time-to-result of 20 minutes, and had a higher diagnostic concordance to routine methods than MALDI-TOF. Other methods evaluated included Cepheid GeneXpert® and a tube coagulase test.
- Abstract #6601. The potential utility of QuickFISH on positive blood cultures to inform antimicrobial stewardship decisions; Tehmina Bharucha, et al. - investigators reported that communicating Gram stain and QuickFISH results together with clinical context (including local resistance patterns) can help inform physicians in early patient management decisions. They concluded that the development of a treatment algorithm based on the results may enhance the clinical benefits of QuickFISH.
Also at the conference, OpGen previewed the QuickFISH Digital Imager, which will automate the QuickFISH procedure and digitize the results. The bench-top instrument is currently in development and is being designed to eliminate the requirement of a fluorescence microscope and darkroom. Development plans include the integration of the Digital Imager with Acuitas Lighthouse™, its bioinformatics platform that will allow rapid analysis of pathogen identity in the context of an antibiotic resistance database, providing decision support for patient management.
“We are encouraged by the impact we are making with premier healthcare institutions such as the NHS Royal Free Trust Hospital with our current QuickFISH products, and are equally excited about our future and the progress we are making with our development programs,” commented Kevin Krenitsky, M.D., OpGen’s president. “We are working to transform the way infectious diseases and antibiotic resistance are managed through the use of molecular and digital technologies. Our aim is to apply the principles of precision medicine to improve patient outcomes, reduce hospital costs and preserve the supply of effective antibiotics.”
Tags: Blood Culture, Staphylococcus aureus
Date Published: April 12, 2016
Source article link: OpGen, Inc » company contact details
FDA-Cleared Liofilchem MIC Test Strip (MTS™) Telavancin (TLV)
Bruker Introduces Novel PCR Assays for Aspergillosis and Carbapenem Resistance
FDA Clearance for BacT/ALERT® VIRTUO™ Fully Automated Blood Culture System
FDA Clears Auto Susceptibility Test Directly from Positive Blood Cultures
Baker Ruskinn Launches New Anaerobic and Microaerophilic Workstations